Citations (15)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Saengsuree Jootar. (2012) CML treatment in Asia–Pacific region. Hematology 17:sup1, pages s72-s74.
Read now
Read now
Kunjahari Medhi, Vinod Raina, Lalit Kumar, Atul Sharma, Sameer Bakhshi, Ritu Gupta & Rajive Kumar. (2010) Response assessment of patients with chronic myeloid leukemia receiving imatinib mesylate (Glivec) therapy: experience from a single center in a developing country. Leukemia & Lymphoma 51:10, pages 1850-1854.
Read now
Read now
Preetha Markose, Ezhilarasi Chendamarai, Poonkuzhali Balasubramanian, Shaji Ramachandran Velayudhan, Vivi M. Srivastava, Vikram Mathews, Biju George, Auro Viswabandya, Alok Srivastava & Mammen Chandy. (2009) Spectrum of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia from India with suspected resistance to imatinib-mutations are rare and have different distributions. Leukemia & Lymphoma 50:12, pages 2092-2095.
Read now
Read now
Articles from other publishers (12)
Angela McLigeyo, Jamilla Rajab, Mohammed Ezzi, Peter Oyiro, Yatich Bett, Andrew Odhiambo, Matilda Ong’ondi, Sitna Mwanzi, Mercy Gatua & NAOthieno- Abinya. (2020) Cytopenia among CML Patients on Imatinib in Kenya: Types, Grades, and Time Course. Advances in Hematology 2020, pages 1-5.
Crossref
Crossref
Prasanth GanesanLalit Kumar. (2017) Chronic Myeloid Leukemia in India. Journal of Global Oncology 3:1, pages 64-71.
Crossref
Crossref
Christianne Bourlon, Carlos Hernandez-Mata, Cesar Vargas-Seraf?n, Mar?a T. Bourlon, Elena Tuna-Aguilar & Alvaro Aguayo. (2016) Fluorescent In Situ Hybridization Monitoring and Effect of Detected Early Responses in the Outcome of Patients With Chronic Phase Chronic Myeloid Leukemia: A Report From a Latin American Country. Clinical Lymphoma Myeloma and Leukemia 16:8, pages 453-459.
Crossref
Crossref
Gerhard Sissolak, Jacques Badenhorst, Janami Steenkamp, Mark Heaney, Vernon Louw, Desmond Schnugh & Pascale Willem. (2015) Treatment Outcomes in CML Patients Treated With Tyrosine Kinase Inhibitors at a Tertiary Teaching Hospital in South Africa. Clinical Lymphoma Myeloma and Leukemia 15:12, pages 803-810.
Crossref
Crossref
Ciani Oriana, Hoyle Martin, Pavey Toby, Cooper Chris, Garside Ruth, Rudin Claudius & Taylor Rod. (2013) Complete Cytogenetic Response and Major Molecular Response as Surrogate Outcomes for Overall Survival in First-Line Treatment of Chronic Myelogenous Leukemia: A Case Study for Technology Appraisal on the Basis of Surrogate Outcomes Evidence. Value in Health 16:6, pages 1081-1090.
Crossref
Crossref
Adam M. Mendizabal, Pat Garcia-Gonzalez & Paul H. Levine. (2013) Regional variations in age at diagnosis and overall survival among patients with chronic myeloid leukemia from low and middle income countries. Cancer Epidemiology 37:3, pages 247-254.
Crossref
Crossref
Sociedade Brasileira de Patologia & Sociedade Brasileira de Pediatria. (2013) Leucemia mieloide crônica. Revista da Associação Médica Brasileira 59:3, pages 220-232.
Crossref
Crossref
A. Mukhopadhyay, S. Dasgupta, S. Mukhopadhyay, C. K. Bose, S. Sarkar, F. Gharami, S. Koner, J. Basak & U. K. Roy. (2011) Imatinib Mesylate Therapy in Patients of Chronic Myeloid Leukemia with Philadelphia Chromosome Positive: An Experience from Eastern India. Indian Journal of Hematology and Blood Transfusion 28:2, pages 82-88.
Crossref
Crossref
Prasanth Ganesan, Tenali Gnana Sagar, Biswajit Dubashi, Rejiv Rajendranath, Krishnarathinam Kannan, Sanju Cyriac & Manjunath Nandennavar. (2011) Nonadherence to Imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia. American Journal of Hematology 86:6, pages 471-474.
Crossref
Crossref
Z. Aziz, J. Iqbal, K. Bano, M. Faisal & M. Akram. (2010) Sustained Superior Long-Term Outcomes and Cytogenetic Responses with Imatinib Mesylate in Chronic Phase Chronic Myeloid Leukaemia: Report from a Developing Country. Japanese Journal of Clinical Oncology 40:6, pages 549-555.
Crossref
Crossref
Ronald D. Barr. (2010) Imatinib mesylate in children and adolescents with cancer. Pediatric Blood & Cancer, pages n/a-n/a.
Crossref
Crossref
Yanmin Zhao, Lizhen Liu, Yingjia Wang, Gongqiang Wu, Xiaoyu Lai, Weijie Cao, Yi Luo, Yamin Tan, Jimin Shi, Wanzhuo Xie, Xiujin Ye, Zhen Cai, Maofang Lin & He Huang. (2009) Efficacy and prognosis of chronic myeloid leukemia treated with imatinib mesylate in a Chinese population. International Journal of Hematology 89:4, pages 445-451.
Crossref
Crossref